Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hunter Website

Kent W. Hunter, Ph.D.

Selected Publications

1)  Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X, Hunter KW.
Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1.
Nat Genet. 37: 1055-1062, 2005.
2)  Hsieh S, Look MP, Sieuwerts AM, Foekens JA, Hunter KW.
Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study.
Breast Cancer Res. 11: R75, 2009.
3)  Hunter KW.
Mouse models of cancer: does the strain matter?.
Nat Rev Cancer. 12: 144-149, 2012.
4)  Hu Y, Wu G, Rusch M, Lukes L, Buetow KH, Zhang J, Hunter KW.
An Integrated Cross-species Transcriptional Network Analysis of Metastatic Susceptibility.
Proc Natl Acad Sci U S A. 109: 3184-9, 2012.
5)  Faraji F, Hu Y, Wu G, Goldberger NE, Walker RC, Zhang J, Hunter KW.
An integrated systems genetics screen reveals the transcriptional structure of inherited predisposition to metastatic disease.
Genome Res. 24: 227-240, 2014.
6)  Alsarraj J, Faraji F, Geiger T, Mattaini K, Williams M, Wu J, Ha N, Merlino T, Walker R, Bosley A, Xiao Z, Andresson T, Esposito D, Smithers N, Lugo D, Prinjha R, Day A, Crawford N, Ozato K, Gardner K, Hunter K.
BRD4 Short Isoform Interacts with RRP1B, SIPA1 and Components of the LINC Complex at the Inner Face of the Nuclear Membrane.
PLoS One. 8: e80746, 2013.
7)  Hu Y, Bai L, Geiger T, Goldberger N, Walker RC, Green JE, Wakefield LM, Hunter KW.
Genetic Background May Contribute to PAM50 Gene Expression Breast Cancer Subtype Assignments.
PLoS ONE. 8: e72287, 2013.
8)  Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM, Ryan Miller C, Raab R, Olopade OI, Gardner K.
Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer.
Nat Commun. 4: 1449, 2013.
9)  Goldberger N, Walker RC, Kim CH, Winter S, Hunter KW.
Inherited Variation in miR-290 Expression Suppresses Breast Cancer Progression by Targeting the Metastasis Susceptibility Gene Arid4b.
Cancer Res. 2013.
10)  Ha NH, Hunter KW.
Using a systems biology approach to understand and study the mechanisms of metastasis.
Wiley Interdiscip Rev Syst Biol Med. 6: 107-14, 2013.
11)  Winter S, Lukes L, Walker R, Welch DR, Hunter KW.
Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis'.
PLoS Genetics. 8: e1002735, 2012.
12)  Alsarraj J, Hunter KW.
Bromodomain-Containing Protein 4: A Dynamic Regulator of Breast Cancer Metastasis through Modulation of the Extracellular Matrix.
Int J Breast Cancer. 2012: 670632, 2012.
13)  Faraji F, Pang Y, Walker RC, Nieves Borges R, Yang L, Hunter KW.
Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity.
PLoS Genet. 8: e1002926, 2012.
14)  Chen M, Nawab A, Yang S, Hollingshead M, Hunter K, Kaye F, Hochwald S, Marquez V, Steeg P, Zajac-Kaye M.
Induction of apoptosis and delay of tumor growth by DNA methyltransferase inhibitor in a genetically engineered mouse model of breast cancer.
Mol Cancer Ther. 11: 370-382, 2012.
15)  Roessler S, Long E, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia H, Ye Q, Qin L, Tang L, He P, Hunter K, Thorgeirsson S, Meltzer P, Wang X.
Integrative Genomic Identification of Genes on 8p Associated with Hepatocellular Carcinoma Progression and Patient Survival.
Gastroenterology. 142: 957-966, 2012.
16)  Collaborative Cross Consortium T.
The genome architecture of the collaborative cross mouse genetic reference population.
Genetics. 190: 389-401, 2012.
Full Text Article. [Journal]
17)  Alsarraj J, Hunter KW.
Willard H, Ginsburg G, eds.
Emerging concepts in metastasis: The impact of genetics, genomics and other tools to investigate the pathobiology of secondary disease in cancer. In: Genomics and Personalized Medicine.
San Diego: Academic Press; 2011. In Press. [Book Chapter]
18)  Crawford N, Hunter KW.
Lyden D, Welch D, Psaila B, eds.
Germline variation and other host determinants of metastatic potential. In: Cancer metastasis: Biologic basis and therapeutics.
New York: Cambridge University Press; 2011. p. 96-104 [Book Chapter]
19)  Alsarraj J, Walker RC, Webster JD, Geiger TR, Crawford NP, Simpson RM, Ozato K, Hunter KW.
Deletion of the Proline-Rich Region of the Murine Metastasis Susceptibility Gene Brd4 Promotes Epithelial-to-Mesenchymal Transition- and Stem Cell-Like Conversion.
Cancer Res. 71: 3121-3131, 2011.
20)  Goldberger NE, Hunter KW.
A systems biology approach to defining metastatic biomarkers and signaling pathways.
Wiley Interdiscip Rev Syst Biol Med. 1: 89-96, 2010.
21)  La Merrill M, Gordon RR, Hunter KW, Threadgill DW, Pomp D.
Dietary fat alters pulmonary metastasis of mammary cancers through cancer autonomous and non-autonomous changes in gene expression.
Clin Exp Metastasis. 27: 107-116, 2010.
22)  Gordon RR, La Merrill M, Hunter KW, Sørensen P, Threadgill DW, Pomp D.
Dietary fat-dependent transcriptional architecture and copy number alterations associated with modifiers of mammary cancer metastasis.
Clin. Exp. Metastasis. 27: 279-93, 2010.
23)  He M, Mangiameli DP, Kachala S, Hunter K, Gillespie J, Bian X, Shen HC, Libutti SK.
Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival.
Clin. Cancer Res. 16: 249-59, 2010.
24)  Korde L, Lusa L, McShate L, Lebowitz P, Lukes L, Camphausen K, Parker J, Swain S, Hunter K, Zujewski J.
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
Breast Cancer Res Treat. 119: 685-99, 2010.
25)  Mendoza A, Hong SH, Osborne T, Khan MA, Campbell K, Briggs J, Eleswarapu A, Buquo L, Ren L, Hewitt SM, Dakir el-H, Garfield S, Walker R, Merlino G, Green JE, Hunter KW, Wakefield LM, Khanna C.
Modeling metastasis biology and therapy in real time in the mouse lung.
J. Clin. Invest. 120: 2979-88, 2010.
26)  Hancock H, Dreher MR, Crawford N, Pollock CB, Shih J, Wood BJ, Hunter K, Frenkel V.
Evaluation of pulsed high intensity focused ultrasound exposures on metastasis in a murine model.
Clin. Exp. Metastasis. 26: 729-38, 2009.
27)  Hunter KW, Alsarraj J.
Gene expression profiles and breast cancer metastasis: a genetic perspective.
Clin. Exp. Metastasis. 26: 497-503, 2009.
28)  Hsieh SM, Smith RA, Lintell NA, Hunter KW, Griffiths LR.
Polymorphisms of the SIPA1 gene and sporadic breast cancer susceptibility.
BMC Cancer. 9: 331, 2009.
29)  Steeg PS, Anderson RL, Bar-Eli M, Chambers AF, Eccles SA, Hunter K, Itoh K, Kang Y, Matrisian LM, Sleeman JP, Theodorescu D, Thompson EW, Welch DR.
Preclinical Drug Development Must Consider the Impact on Metastasis.
Clin. Cancer Res. 15: 4529-4530, 2009.
30)  Qian X, Li G, Vass W, Papageorge A, Asnaghi L, Tosato G, Hunter KW, Lowy DR.
Tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis.
Cancer Cell. 16: 246-258, 2009.
31)  Crawford NP, Yang H, Mattaini KR, Hunter KW.
The metastasis efficiency modifier ribosomal RNA processing 1 homolog B (RRP1B) is a chromatin-associated factor.
J. Biol. Chem. 284: 28660-73, 2009.
32)  Lukes L, Crawford NP, Walker R, Hunter KW.
The origins of breast cancer prognostic gene expression profiles.
Cancer Res. 69: 310-8, 2009.
33)  Crawford NP, Hunter KW.
Emerging concepts in metastasis: The impact of genetics, genomics and other tools to investigate the pathobiology of secondary disease in cancer. In: Genomics and Personalized Medicine. Volume 2.
San Diego: Academic Press; 2008. p. 977-989 [Book Chapter]
34)  Crawford NP, Alsarraj J, Lukes L, Walker R, Officewala J, Yang H, Lee M, Ozato K, Hunter KW.
Bromodomain 4 activation predicts breast cancer survival.
Proc Natl Acad Sci U S A. 105: 6380-6385, 2008.
35)  Gaudet MM, Hunter K, Pharoah P, Dunning AM, Driver K, Lissowska J, Sherman M, Peplonska B, Brinton LA, Chanock S, Garcia-Closas M.
Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis.
Int. J. Cancer. 124: 1716-20, 2008.
36)  Gordon RR, Hunter KW, Sørensen P, Pomp D.
Genotype x diet interactions in mice predisposed to mammary cancer. I. Body weight and fat.
Mamm. Genome. 19: 163-78, 2008.
37)  Gordon RR, Hunter KW, La Merrill M, Sørensen P, Threadgill DW, Pomp D.
Genotype x diet interactions in mice predisposed to mammary cancer: II. Tumors and metastasis.
Mamm. Genome. 19: 179-89, 2008.
38)  Hunter K, Chambers AF.
Introduction to special issue on 'epigenetic and physiological regulation of metastasis'.
Clin. Exp. Metastasis. [Epub ahead of print], 2008.
39)  Hunter KW, Crawford NP, Alsarraj J.
Mechanisms of metastasis.
Breast Cancer Res. 10 Suppl 1: S2, 2008.
40)  Winter SF, Hunter KW.
Mouse Modifier Genes in Mammary Tumorigenesis and Metastasis.
J Mammary Gland Biol Neoplasia. 13: 337-342, 2008.
41)  Crawford NP, Walker RC, Lukes L, Officewala JS, Williams RW, Hunter KW.
The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival.
Clin. Exp. Metastasis. 25: 357-369, 2008.
42)  Hunter KW, Crawford NP.
The Future of QTL Mapping to Diagnose Disease in Mice in the Age of Whole-Genome Association Studies.
Annu. Rev. Genet. 42: 131-41, 2008.
43)  Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC.
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
Clin. Cancer Res. 13: 2168-77, 2007.
44)  Hsieh SM, Lintell NA, Hunter KW.
Germline polymorphisms are potential metastasis risk and prognosis markers in breast cancer.
Breast Dis. 26: 157-62, 2007.
45)  Wakefield L, Hunter K.
Introduction to breast disease review issue on metastasis.
Breast Dis. 26: 1-2, 2007.
46)  Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, Walker RC, Lukes L, Rowe W, Zhang J, Ambs S, Anton-Culver H, Hunter KW.
Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis.
PLOS Genetics. 3: 2296-2311, 2007.
47)  Hunter KW.
Context-dependent cancer risk.
Nat. Genet. 38: 864-5, 2006.
48)  Hunter KW, Crawford NP.
Germ line polymorphism in metastatic progression.
Cancer Res. 66: 1251-4, 2006.
49)  Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW.
Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer.
Breast Cancer Res. 8: R16, 2006.
50)  Hunter K.
Host genetics influence tumour metastasis.
Nature Reviews Cancer. 6: 141-146, 2006.
51)  Crawford NP, Hunter KW.
New perspectives on hereditary influences in metastatic progression.
Trends in Genetics. 22: 555-561, 2006.
52)  Yang H, Yu LR, Yi M, Lucas DA, Lukes L, Lancaster M, Chan KC, Issaq HJ, Stephens RM, Conrads TP, Veenstra TD, Hunter KW.
Parallel analysis of transcript and translation profiles: identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications.
J. Proteome Res. 5: 1555-67, 2006.
53)  Zhang J, Hunter KW, Gandolph M, Rowe WL, Finney RP, Kelley JM, Edmonson M, Buetow KH.
A high-resolution multistrain haplotype analysis of laboratory mouse genome reveals three distinctive genetic variation patterns.
Genome Res. 15: 241-9, 2005.
54)  Hunter KW, Crawford NP, Lukes L.
Inherited metastasis susceptibility and the implications for clinical prognosis.
Discov Med. 5: 511-5, 2005.
55)  Hunter KW, Crawford NP, Lukes L.
Inherited metastasis susceptibility and the implications for clinical prognosis.
Discovery Medicine. 5: 511-516, 2005.
56)  Yang H, Crawford N, Lukes L, Finney R, Lancaster M, Hunter KW.
Metastasis Predictive Signature Profiles Pre-exist in Normal Tissues.
Clin Exp Metastasis. 22: 593-603, 2005.
57)  Khanna C, Hunter K.
Modeling metastasis in vivo.
Carcinogenesis. 26: 513-523, 2005.
58)  Lancaster M, Rouse J, Hunter KW.
Modifiers of mammary tumor progression and metastasis on mouse chromosomes 7, 9, and 17.
Mamm Genome. 16: 120-6, 2005.
59)  Borowsky AD, Namba R, Young LJ, Hunter KW, Hodgson JG, Tepper CG, McGoldrick ET, Muller WJ, Cardiff RD, Gregg JP.
Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior.
Clin Exp Metastasis. 22: 47-59, 2005.
60)  Hunter K.
The Intersection of Inheritance and Metastasis: The Role and Implications of Germline Polymorphism in Tumor Dissemination.
Cell Cycle. 4: 1719-1721, 2005.
61)  Threadgill DW, Hunter KW, Zou F, Manly KF.
Holland E, eds.
Cancer Modifiers: Detection, Localization, and Identification. In: Mouse Models of Human Cancer.
New York: John Wiley & Sons; 2004. p. 263-291 [Book Chapter]
62)  Yang H, Rouse J, Lukes L, Lancaster M, Veenstra T, Zhou M, Shi Y, Park YG, Hunter K.
Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis.
Clin Exp Metastasis. 21: 719-35, 2004.
63)  Hunter KW.
Ezrin, a key component in tumor metastasis.
Trends Mol Med. 10: 201-4, 2004.
64)  Hunter K.
Genetic and Genomic Studies of Breast Cancer Dissemination.
Breast Disease. 3: 83-91, 2004.
65)  Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET.
Global Expression Profiling Identifies Potential Metastasis Modifier Genes in MMTV-PyMT Transgenic Mice: correlation to human disease.
Cancer Research. 56: 5973-5981, 2004.
66)  Hunter KW.
Host genetics and tumour metastasis.
Brit. J. Cancer. 90: 752-755, 2004.
67)  Churchill GA, Airey DC, Allayee H, Angel JM, Attie AD, Beatty J, Beavis WD, Belknap JK, Bennett B, Berrettini W, Bleich A, Bogue M, Broman KW, Buck KJ, Buckler E, Burmeister M, Chesler EJ, Cheverud JM, Clapcote S, Cook MN, Cox RD, Crabbe JC, Crusio WE, Darvasi A, Deschepper CF, Doerge RW, Farber CR, Forejt J, Gaile D, Garlow SJ, Geiger H, Gershenfeld H, Gordon T, Gu J, Gu W, de Haan G, Hayes NL, Heller C, Himmelbauer H, Hitzemann R, Hunter K, Hsu HC, Iraqi FA, Ivandic B, Jacob HJ, Jansen RC, Jepsen KJ, Johnson DK, Johnson TE, Kempermann G, Kendziorski C, Kotb M, Kooy RF, Llamas B, Lammert F, Lassalle JM, Lowenstein PR, Lu L, Lusis A, Manly KF, Marcucio R, Matthews D, Medrano JF, Miller DR, Mittleman G, Mock BA, Mogil JS, Montagutelli X, Morahan G, Morris DG, Mott R, Nadeau JH, Nagase H, Nowakowski RS, O'Hara BF, Osadchuk AV, Page GP, Paigen B, Paigen K, Palmer AA, Pan HJ, Peltonen-Palotie L, Peirce J, Pomp D, Pravenec M, Prows DR, Qi Z, Reeves RH, Roder J, Rosen GD, Schadt EE, Schalkwyk LC, Seltzer Z, Shimomura K, Shou S, Sillanpää MJ, Siracusa LD, Snoeck HW, Spearow JL, Svenson K, Tarantino LM, Threadgill D, Toth LA, Valdar W, de Villena FP, Warden C, Whatley S, Williams RW, Wiltshire T, Yi N, Zhang D, Zhang M, Zou F, Complex Trait Consortium .
The Collaborative Cross, a community resource for the genetic analysis of complex traits.
Nat Genet. 36: 1133-7, 2004.
68)  Welch DR, Hunter KW.
A new member of the growing family of metastasis suppressors identified in prostate cancer.
J Natl Cancer Inst. 95: 839-41, 2003.
69)  Hunter KW.
Allelic diversity of the host genetic background as a determinant in tumor metastatic dissemination.
Cancer Letters. 200: 97-105, 2003.
70)  Hunter K, Welch DR, Liu ET.
Genetic background is an important determinant of metastatic potential.
Nat Genet. 34: 23-24, 2003.
71)  Park YG, Clifford R, Buetow KH, Hunter KW.
Multiple cross and inbred strain haplotype mapping of complex-trait candidate genes.
Genome Res. 13: 118-121, 2003.
72)  McGlynn KA, Hunter K, LeVoyer T, Roush J, Wise P, Michielli RA, Shen FM, Evans AA, London WT, Buetow KH.
Susceptibility to Aflatoxin B(1)-related Primary Hepatocellular Carcinoma in Mice.
Cancer Research. 63: 4594-4601, 2003.
73)  Abiola O, Angel JM, Avner P, Bachmanov AA, Belknap JK, Bennett B, Blankenhorn EP, Blizard DA, Bolivar V, Brockmann GA, Buck KJ, Bureau JF, Casley WL, Chesler EJ, Cheverud JM, Churchill GA, Cook M, Crabbe JC, Crusio WE, Darvasi A, de Haan G, Dermant P, Doerge RW, Elliot RW, Farber CR, Flaherty L, Flint J, Gershenfeld H, Gibson JP, Gu J, Gu W, Himmelbauer H, Hitzemann R, Hsu HC, Hunter K, Iraqi FF, Jansen RC, Johnson TE, Jones BC, Kempermann G, Lammert F, Lu L, Manly KF, Matthews DB, Medrano JF, Mehrabian M, Mittlemann G, Mock BA, Mogil JS, Montagutelli X, Morahan G, Mountz JD, Nagase H, Nowakowski RS, O'Hara BF, Osadchuk AV, Paigen B, Palmer AA, Peirce JL, Pomp D, Rosemann M, Rosen GD, Schalkwyk LC, Seltzer Z, Settle S, Shimomura K, Shou S, Sikela JM, Siracusa LD, Spearow JL, Teuscher C, Threadgill DW, Toth LA, Toye AA, Vadasz C, Van Zant G, Wakeland E, Williams RW, Zhang HG, Zou F, Complex Trait Consortium .
The nature and identification of quantitative trait loci: a community’s view.
Nature Reviews Genetics. 4: 911-915, 2003.
74)  Montagna C, Lyu MS, Hunter K, Lukes L, Lowther W, Reppert T, Hissong B, Weaver Z, Ried T.
The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines.
Cancer Res. 63: 2179-87, 2003.
75)  Cozma D, Lukes L, Rouse J, Qiu TH, Liu ET, Hunter KW.
A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers.
Genome Res. 12: 969-975, 2002.
76)  Park YG, Lukes L, Yang H, Debies MT, Samant RS, Welch DR, Lee M, Hunter KW.
Comparative sequence analysis in eight inbred strains of the metastasis modifier QTL candidate gene Brms1.
Mamm Genome. 13: 289-92, 2002.
77)  Hunter KW, Williams RW.
Complexities of cancer research: mouse genetic models.
ILAR J. 43: 80-8, 2002.
78)  Threadgill DW, Hunter KW, Williams RW.
Genetic dissection of complex and quantitative traits: from fantasy to reality via a community effort.
Mamm Genome. 13: 175-8, 2002.
79)  Hunter KW, Broman KW, Voyer TL, Lukes L, Cozma D, Debies MT, Rouse J, Welch DR.
Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1.
Cancer Res. 61: 8866-8872, 2001.
80)  Le Voyer T, Rouse J, Lu Z, Lifsted T, Williams M, Hunter KW.
Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density.
Genomics. 74: 253-261, 2001.
81)  Le Voyer T, Lu Z, Babb J, Lifsted T, Williams M, Hunter K.
An epistatic interaction controls the latency of a transgene-induced mammary tumor.
Mamm Genome. 11: 883-889, 2000.
82)  Le Voyer TE, Hunter KW.
Microsatellite DNA variants among the FVB/NJ, C58/J, and I/LnJ mouse strains.
Mamm. Genome. 10: 542-3, 1999.
83)  Williams RW, Angel JM, Holdener BC, Oakey R, Hunter KW.
Mouse chromosome 7.
Mamm. Genome. 10: 947, 1999.
84)  Williams RW, Holdener BC, Angel JM, Oakey R, Hunter KW.
Encyclopedia of the mouse genome VII. Mouse chromosome 7.
Mamm. Genome. 8 Spec No: S136-59, 1998.
85)  Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW.
Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression.
Int J Cancer. 77: 640-4, 1998.
86)  Hunter KW, Riba L, Schalkwyk L, Clark M, Resenchuk S, Beeghly A, Su J, Tinkov F, Lee P, Ramu E, Lehrach H, Housman D.
Toward the construction of integrated physical and genetic maps of the mouse genome using interspersed repetitive sequence PCR (IRS-PCR) genomics.
Genome Res. 6: 290-9, 1996.
87)  Hunter KW, Ontiveros SD, Watson ML, Stanton VP, Gutierrez P, Bhat D, Rochelle J, Graw S, Ton C, Schalling M.
Rapid and efficient construction of yeast artificial chromosome contigs in the mouse genome with interspersed repetitive sequence PCR (IRS-PCR): generation of a 5-cM, > 5 megabase contig on mouse chromosome 1.
Mamm. Genome. 5: 597-607, 1994.
88)  Hunter KW, Watson ML, Rochelle J, Ontiveros S, Munroe D, Seldin MF, Housman DE.
Single-strand conformational polymorphism (SSCP) mapping of the mouse genome: integration of the SSCP, microsatellite, and gene maps of mouse chromosome 1.
Genomics. 18: 510-9, 1993.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/19/2014.